about
Piroxicam confer neuroprotection in Cerebral Ischemia by inhibiting Cyclooxygenases, Acid- Sensing Ion Channel-1a and Aquaporin-4: an in silico comparison with Aspirin and Nimesulide.Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease.Contribution of β-phenethylamine, a component of chocolate and wine, to dopaminergic neurodegeneration: implications for the pathogenesis of Parkinson's disease.Neuroprotective potential of silymarin against CNS disorders: insight into the pathways and molecular mechanisms of action.Cholesterol - A putative endogenous contributor towards Parkinson's disease.The potential physiological crosstalk and interrelationship between two sovereign endogenous amines, melatonin and homocysteine.Cholesterol in Pancreatic β-Cell Death and Dysfunction: Underlying Mechanisms and Pathological Implications.L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room.Chronic exposure of homocysteine in mice contributes to dopamine loss by enhancing oxidative stress in nigrostriatum and produces behavioral phenotypes of Parkinson's disease.Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism.L-DOPA-induced 6-hydroxydopamine production in the striata of rodents is sensitive to the degree of denervation.Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents.Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats.Long-term L-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats.Global loss of acetylcholinesterase activity with mitochondrial complexes inhibition and inflammation in brain of hypercholesterolemic mice.Melatonin protects against behavioral deficits, dopamine loss and oxidative stress in homocysteine model of Parkinson's disease.Getting Closer to an Effective Intervention of Ischemic Stroke: The Big Promise of Stem Cell.Hypercholesterolemia causes psychomotor abnormalities in mice and alterations in cortico-striatal biogenic amine neurotransmitters: Relevance to Parkinson's disease.A highly reproducible mice model of chronic kidney disease: Evidences of behavioural abnormalities and blood-brain barrier disruption.Activation of NMDA receptor by elevated homocysteine in chronic liver disease contributes to encephalopathy.Inhibition of matrix metalloproteinase-2 and 9 by Piroxicam confer neuroprotection in cerebral ischemia: an in silico evaluation of the hypothesis.L-DOPA induced-endogenous 6-hydroxydopamine is the cause of aggravated dopaminergic neurodegeneration in Parkinson's disease patients.L-DOPA treatment in MPTP-mouse model of Parkinson's disease potentiates homocysteine accumulation in substantia nigra.Disturbed purine nucleotide metabolism in chronic kidney disease is a risk factor for cognitive impairment.β-phenethylamine--a phenylalanine derivative in brain--contributes to oxidative stress by inhibiting mitochondrial complexes and DT-diaphorase: an in silico study.Noncoding RNAs in ischemic stroke: time to translate.Oxidative stress and mitochondrial dysfunction are the underlying events of dopaminergic neurodegeneration in homocysteine rat model of Parkinson's disease.Attenuation of Aluminum Chloride-Induced Neuroinflammation and Caspase Activation Through the AKT/GSK-3β Pathway by Hesperidin in Wistar Rats.Piroxicam inhibits NMDA receptor-mediated excitotoxicity through allosteric inhibition of the GluN2B subunit: an in silico study elucidating a novel mechanism of action of the drug.Novel Targets for Parkinson's Disease: Addressing Different Therapeutic Paradigms and ConundrumsTherapeutic spectrum of interferon-β in ischemic strokeTrigonelline therapy confers neuroprotection by reduced glutathione mediated myeloperoxidase expression in animal model of ischemic strokeNeuroprotective attributes of L-theanine, a bioactive amino acid of tea, and its potential role in Parkinson's disease therapeuticsGarcinol, a multifaceted sword for the treatment of Parkinson's disease1-Methyl-4-Phenylpyridinium-Induced Death of Differentiated SH-SY5Y Neurons Is Potentiated by CholesterolInflammasomes in stroke: a triggering role for acid-sensing ion channelsMitochondrial Dysfunction in Stroke: Implications of Stem Cell TherapyA Friend or Foe: Calcineurin across the Gamut of Neurological DisordersAccumulation of Cholesterol and Homocysteine in the Nigrostriatal Pathway of Brain Contributes to the Dopaminergic Neurodegeneration in Mice
P50
Q35775475-93429DFB-92FC-4641-86AC-E17721876599Q36272936-37DFD294-EDFC-4FAC-8109-17B1EC0A93EAQ37242415-AD163D89-5F3C-4153-8489-C509A4582D58Q38098089-1C6600CA-5B30-4FA0-8E10-BEE7EBCBF431Q38151947-55328AC9-006E-4146-8BDE-90799AFEE8BDQ38558801-2D1EDE89-D7DD-4FCF-A472-23E6E5DD2A64Q38568442-06BC950D-1476-4705-91FC-0D8DE0BAF2D1Q38675956-55DE2CF2-574C-4E36-8BBE-E95F8F1A5A7FQ38694393-4DD71302-2E0B-4570-AE6D-3DC21EDAA4A1Q41683178-2DDC3D1D-620D-4244-8C5E-61549A96B11CQ43063094-E1C22F9B-3E81-4ED4-B656-3CF2C1057ADDQ43237341-615CBEE3-A001-4685-A7BD-6A3BC6399546Q43268625-C0966C5C-5F39-41DF-91A8-D9E569B7EBDEQ45293625-A7C79BBC-BC11-4D1B-8579-C35BD88A297DQ46952543-196DDF54-3DE9-4B0B-83DC-431095F6F787Q47106191-63895811-1BF6-444E-A5A6-22E2330A5854Q47402522-C58EF214-5DF2-40F5-8EA8-B6AC95C548E1Q47405412-84E3F267-BD8F-4455-9246-E27E7E043EF3Q47975815-878CF50F-1804-40AB-94AA-02C3D866D8D9Q48030048-8FFC4199-3564-4E8F-AC30-62253AF97D46Q48226252-8E741DC4-95C9-4171-A479-69049DBFF357Q48430442-DC883DB2-E03B-404B-A51A-1C2914A8A0EDQ48491459-E2FF4F2E-D17E-46FB-AE55-00F9FEA0C3A4Q48685445-9E61D654-B1B7-49FC-BED7-6C13AFCBFEABQ50180114-317EBF36-20BC-40B8-B25C-303E8226E516Q51023901-BF903949-4780-4A25-8ECE-622E4DAB4413Q52570379-70B9A93E-0B09-40D5-B1BD-7B601D7B8799Q52840681-EAC9975A-FE05-4542-A6C2-D9CF1DE9FF8CQ53403527-D79C88DE-E22E-491A-BD8B-A06E6204BBF4Q53675630-37711062-2AE0-49B8-8028-048AF0FD64EDQ57176356-EFF82434-8A78-434B-BD2C-189101B1C41CQ57464040-970DF3A2-1978-4D54-B1CB-9EAAC1324717Q58598913-7F962FE8-C10E-4A38-8DE7-A6196E3A5A9DQ64764676-F78DF776-C8A1-41CB-BBAE-867C5E8159A6Q64768776-3B4C840C-C6C0-463A-ABF1-220EC9BCC2CDQ88925411-3AC93539-1A07-4EBD-8E93-E323DF9DE454Q89149588-66AF0FD3-D0C9-4649-8F28-D7866A9B3F0CQ89172402-3EB465C2-B91F-4F2D-A54E-F6CDF3616AC8Q90652114-7B313FE7-76DD-4E51-94B6-3B0D49B7C8F7Q90741110-AD397455-B2E4-478A-AEB4-9CA93BFB517A
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Anupom Borah
@ast
Anupom Borah
@en
Anupom Borah
@es
type
label
Anupom Borah
@ast
Anupom Borah
@en
Anupom Borah
@es
prefLabel
Anupom Borah
@ast
Anupom Borah
@en
Anupom Borah
@es
P106
P1153
23479386400
P31
P496
0000-0002-6283-5367